Now that we know they have a TD drug that works in the 100 mg dose the pps should rise.
There was nothing in the pps for TD. Elagolix is still undervalued. This should go to $25 fairly soon.
"Deutsche Bank believes that Neuricrine has several key catalysts over the next 12 months. The firm thinks that investors are underestimating the potential of the company's Elagolix drug in uterine fibroids. Deutsche keeps a Buy rating on the stock."